Grant of Share Options

RNS Number : 7531K

Shield Therapeutics PLC

11 July 2017

 

Shield Therapeutics plc

("Shield" or the "Company")

Grant of Share Options

London, UK, 11 July 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that the Company has today granted, in aggregate, 1,972,487 share awards in the form of options over Ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's 2016 Long-term Incentive Plan ("LTIP") and the 2016 Company Share Option Plan ("CSOP"). The Company has granted 1,683,877 options under the LTIP and 288,610 options under the CSOP.

The LTIP options will be exercisable at a price of 1.5 pence per Ordinary Share, after a period of 3 years until the day before the tenth anniversary of the grant, subject to the achievement of clear performance criteria set out in the Company's Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com). 

The CSOP options are exercisable at an exercise price of 157.5 pence per Ordinary Share from the third anniversary of grant until the day before the tenth anniversary of grant. There are no additional performance conditions attaching to the CSOP options.

This grant of options is part of the Company's long-term incentive arrangements designed to align the interests of the shareholders and executives.

In accordance with the requirements of the EU Market Abuse Regulation the following options have been granted to PDMRs under the LTIP and CSOP.

Name	LTIP options granted	Total number of LTIP options held following grant	CSOP options granted	Total number of CSOP options held following grant
Carl Sterritt, CEO	263,512	572,736	19,048	19,048
Joanne Estell, CFO	285,714	285,714	19,048	19,048
Paul Steckler, PDMR	162,698	356,618	19,048	19,048
Mark Sampson, PDMR	165,952	321,088	19,048	19,048

Following the grant of the LTIP and CSOP options, the total number of Ordinary Shares outstanding under share incentive schemes arrangements will be 3,014,749 representing 2.59% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

LTIP

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Carl Sterritt                        Director / PDMR Joanne Estell                     Director / PDMR Paul Steckler                     PDMR    Mark Sampson                  PDMR
2	Reason for the notification
a)	Position/status	All PDMRs of Shield Therapeutics
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Option over ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Grant of Options over ordinary shares in accordance with the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Exercise price: 1.5p Volumes: Carl Sterritt                        263,512 Joanne Estell                     285,714 Paul Steckler                     162,698 Mark Sampson                  165,952
d)	Aggregated information -Aggregated volume -Price	877,876  Exercise price: 1.5p
e)	Date of the transaction	11 July 2017
f)	Place of the transaction	Outside a trading venue

CSOP

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Carl Sterritt                        Director / PDMR Joanne Estell                     Director / PDMR Paul Steckler                     PDMR    Mark Sampson                  PDMR
2	Reason for the notification
a)	Position/status	All PDMRs of Shield Therapeutics
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Option over ordinary shares of 157.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Grant of Options over ordinary shares in accordance with the Company's Share Option Scheme
c)	Price(s) and volume(s)	Exercise price: 157.5p Volumes: Carl Sterritt                        19,048 Joanne Estell                     19,048 Paul Steckler                     19,048 Mark Sampson                  19,048
d)	Aggregated information -Aggregated volume -Price	76,192 Exercise price: 157.5p
e)	Date of the transaction	11 July 2017
f)	Place of the transaction	Outside a trading venue

-Ends-

For further information please contact:

Shield Therapeutics plc	[phone]
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer
Nominated Advisor and Joint Broker Liberum Capital Limited Christopher Britton/Steve Pearce	[phone]
Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden	[phone]
Financial PR Advisor Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	[phone] [e-mail]

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com. 

 

END

 

 

DSHUAVORBBABAAR